Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing Point Bio's 177Lu-PNT2002 in mCRPC after recent data presented at ESMO 2022

Ticker(s): PNT, NVS

Who's the expert?

Institution: Arizona Center for Cancer Care

Board-certified radiation oncologist with expertise in the management of breast, prostate and gastrointestinal cancers in a Multispecialty Oncology Group.
Currently manages ~100 patients with prostate cancer with an interest in utilizing new and advanced treatment techniques to minimize side effects
Member of the American Society for Therapeutic Radiology and Oncology, American Brachytherapy Society, American College of Radiology and the Arizona Radiological Society

Interview Goal

This conversation will focus on the standard of care for metastatic castration resistant prostate cancer and the potential of new therapies in development with a specific focus on 177Lu-PNT2002. We will dig into the recent data from the Phase 3 SPLASH study of 177Lu-PNT2002 from Point Biopharma,and how it may compare to Pluvicto with an oncologist who treats mCRPC.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.